According to the company, the CollaRx lidocaine sponge is a lyophilized collagen sponge containing purified type-I collagen protein and lidocaine, a locally acting anesthetic.
The product is intended to be used for the management of painful wounds including: diabetic ulcers, venous ulcers, pressure ulcers, ulcers caused by mixed vascular etiologies, full-thickness and partial thickness wounds, abrasions, traumatic wounds, first and second degree burns and dehisced surgical wounds.
Michael Myers, president and CEO of Innocoll, said: “I am very pleased about the progress that we have made with the CollaRx lidocaine sponge. This marks our third medical device filing in the US, and demonstrates the versatility of our collagen based drug delivery technology.”